Disclaimer: This is not financial advice. Data sourced from SEC EDGAR and Polygon.io. Past performance does not guarantee future results. Always conduct your own research before making investment decisions.
Recursion Pharmaceuticals, Inc. Class A Common Stock (RXRX) has a market cap of $2.00B with year-over-year revenue growth of +32.0%. Net margin stands at -788.0%. The stock trades at a P/E ratio of -4.3.
Compared to other companies in the BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) sector, RXRX posted revenue growth of +32.0% and trades at a P/E of -4.3.
Disclaimer: This is not financial advice. Data sourced from SEC EDGAR and Polygon.io. Past performance does not guarantee future results. Always conduct your own research before making investment decisions.